Latest Insider Transactions at Veracyte, Inc. (VCYT)
This section provides a real-time view of insider transactions for Veracyte, Inc. (VCYT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERACYTE, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERACYTE, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2024
|
Muna Bhanji Director |
SELL
Open market or private sale
|
Direct |
3,870
-14.35%
|
$77,400
$20.32 P/Share
|
|
Jun 07
2024
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
2,500
-7.02%
|
$50,000
$20.97 P/Share
|
|
Jun 07
2024
|
Karin Eastham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+6.56%
|
$25,000
$10.41 P/Share
|
|
Jun 02
2024
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,087
-2.22%
|
$21,740
$20.75 P/Share
|
|
Jun 02
2024
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,314
-1.54%
|
$26,280
$20.75 P/Share
|
|
Jun 02
2024
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,746
-1.74%
|
$114,920
$20.75 P/Share
|
|
Jun 02
2024
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,919
-1.97%
|
$38,380
$20.75 P/Share
|
|
Jun 02
2024
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,462
-2.36%
|
$69,240
$20.75 P/Share
|
|
May 28
2024
|
Muna Bhanji Director |
SELL
Open market or private sale
|
Direct |
1,539
-5.4%
|
$32,319
$21.0 P/Share
|
|
Apr 01
2024
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
10,000
-23.19%
|
$210,000
$21.65 P/Share
|
|
Apr 01
2024
|
Karin Eastham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.82%
|
$130,000
$13.19 P/Share
|
|
Mar 15
2024
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,971
-1.78%
|
$125,391
$21.1 P/Share
|
|
Mar 15
2024
|
Marc Stapley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,780
+3.39%
|
-
|
|
Mar 15
2024
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,189
-1.47%
|
$45,969
$21.1 P/Share
|
|
Mar 15
2024
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,318
+2.82%
|
-
|
|
Mar 06
2024
|
Phillip G. Febbo Chief Scientific & Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,904
+30.01%
|
-
|
|
Mar 06
2024
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,856
+29.28%
|
-
|
|
Mar 06
2024
|
Jonathan Wygant VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,942
+32.8%
|
-
|
|
Mar 06
2024
|
Annie Mc Guire SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
49,880
+33.88%
|
-
|
|
Mar 06
2024
|
John Leite Chief Commercial Officer-CLIA |
BUY
Grant, award, or other acquisition
|
Direct |
49,880
+36.83%
|
-
|
|
Mar 06
2024
|
Marc Stapley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
114,724
+26.15%
|
-
|
|
Mar 02
2024
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,347
-8.39%
|
$104,328
$24.0 P/Share
|
|
Mar 02
2024
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,286
-5.97%
|
$318,864
$24.0 P/Share
|
|
Mar 02
2024
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
3,008
-7.78%
|
$72,192
$24.0 P/Share
|
|
Mar 02
2024
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,112
-6.73%
|
$146,688
$24.0 P/Share
|
|
Mar 02
2024
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,337
-8.51%
|
$56,088
$24.0 P/Share
|
|
Mar 01
2024
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
10,000
-21.01%
|
$240,000
$24.36 P/Share
|
|
Mar 01
2024
|
Evan/ Fa Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+17.36%
|
$130,000
$13.19 P/Share
|
|
Dec 02
2023
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,800
-1.94%
|
$46,800
$26.54 P/Share
|
|
Dec 02
2023
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
556
-1.42%
|
$14,456
$26.54 P/Share
|
|
Dec 02
2023
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,203
-1.42%
|
$83,278
$26.54 P/Share
|
|
Dec 02
2023
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
507
-1.84%
|
$13,182
$26.54 P/Share
|
|
Dec 02
2023
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
803
-1.53%
|
$20,878
$26.54 P/Share
|
|
Oct 02
2023
|
Phillip G. Febbo Chief Scientific & Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,182
+50.0%
|
-
|
|
Sep 02
2023
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,729
-3.18%
|
$44,954
$26.7 P/Share
|
|
Sep 02
2023
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
2,222
-5.36%
|
$57,772
$26.7 P/Share
|
|
Sep 02
2023
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,652
-3.79%
|
$94,952
$26.7 P/Share
|
|
Sep 02
2023
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,247
-4.33%
|
$32,422
$26.7 P/Share
|
|
Sep 02
2023
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,204
-1.4%
|
$83,304
$26.7 P/Share
|
|
Jul 19
2023
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Indirect |
3,090
-8.08%
|
$92,700
$30.17 P/Share
|
|
Jul 19
2023
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
838
-2.18%
|
$25,140
$30.14 P/Share
|
|
Jul 18
2023
|
John L Bishop Director |
SELL
Open market or private sale
|
Direct |
10,000
-23.19%
|
$300,000
$30.5 P/Share
|
|
Jul 18
2023
|
John L Bishop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.82%
|
$60,000
$6.37 P/Share
|
|
Jul 18
2023
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Indirect |
7,441
-16.28%
|
$223,230
$30.19 P/Share
|
|
Jul 18
2023
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
2,324
-5.7%
|
$69,720
$30.16 P/Share
|
|
Jul 17
2023
|
John L Bishop Director |
SELL
Open market or private sale
|
Direct |
10,000
-23.19%
|
$300,000
$30.0 P/Share
|
|
Jul 17
2023
|
John L Bishop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.82%
|
$60,000
$6.37 P/Share
|
|
Jul 17
2023
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Indirect |
23,949
-34.38%
|
$718,470
$30.07 P/Share
|
|
Jul 17
2023
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
19,095
-31.9%
|
$572,850
$30.07 P/Share
|
|
Jun 16
2023
|
Muna Bhanji Director |
SELL
Open market or private sale
|
Direct |
5,893
-8.59%
|
$153,218
$26.76 P/Share
|